Home » Authors » Brady Huggett

Articles by Brady Huggett

Igeneon Expands Celltrion Deal For Up To $20M More

Feb. 8, 2006

By Brady Huggett

Maxygen, Roche Enter $95M Recombinant Factor VIIa Deal

Dec. 16, 2005

By Brady Huggett

Maxygen, Roche Enter $95M Recombinant Factor VIIa Deal

Dec. 16, 2005

By Brady Huggett

Gauging State Of European Biotechnology VC Industry

Dec. 5, 2005

By Brady Huggett

Gauging State Of European Biotechnology VC Industry

Dec. 5, 2005

By Brady Huggett

VC Syndication Key For Young European Biotechnology Firms

Dec. 1, 2005

By Brady Huggett

VC Syndication Key For Young European Biotechnology Firms

Dec. 1, 2005

By Brady Huggett

Serenex In-Licenses Phase II Drug, Raises $30M Series C

Oct. 6, 2005

By Brady Huggett

Serenex In-Licenses Phase II Drug, Raises $30M Series C

Oct. 6, 2005

By Brady Huggett

RenaMed Forms Deal With Genzyme For Up To $43M

Sep. 29, 2005

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...